
    
      The primary objective of this study is to show that the combination treatment CS/GH has
      comparable efficacy to CE in pain reduction from baseline to 6 months of treatment measured
      with the Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain subscale in
      knee OA patients with moderate to severe pain.
    
  